The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours: A non-cisplatin-based regimen.
Waleed Badreldin
No relevant relationships to disclose
Simon Chowdhury
No relevant relationships to disclose
Stephen John Harland
Honoraria - Sanofi
Danish Mazhar
No relevant relationships to disclose
Thomas Powles
No relevant relationships to disclose
Peter Wilson
No relevant relationships to disclose
Jonathan Shamash
No relevant relationships to disclose